Results 1 to 10 of about 39,927 (270)
Orphanet Journal of Rare Diseases, 2007 Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine ...
Pollock Neil +4 more
doaj +7 more sources
Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье, 2022 Malignant hyperthermia manifests as hypermetabolism of striated voluntary muscle. Generally, this condition occurs during general anesthesia when inhalational anesthetics and succinylcholine are used.
S. N. Ionov +2 more
doaj +14 more sources
Korean Journal of Anesthesiology, 2012 Malignant hyperthermia (MH) is an uncommon, life-threatening pharmacogenetic disorder of the skeletal muscle. It presents as a hypermetabolic response in susceptible individuals to potent volatile anesthetics with/without depolarizing muscle relaxants ...
Dong-Chan Kim
doaj +10 more sources
Malignant Hyperthermia in PICU—From Diagnosis to Treatment in the Light of Up-to-Date Knowledge [PDF]
Children, 2022 Malignant Hyperthermia (MH) is a rare, hereditary, life-threatening disease triggered by volatile anesthetics and succinylcholine. Rarely, MH can occur after non-pharmacological triggers too. MH was detected more often in children and young adults, which
Martina Klincová +4 more
doaj +2 more sources
Malignant hyperthermia: patient undergoing limb debridement surgery—a case report [PDF]
Journal of Medical Case ReportsBackground Malignant hyperthermia is a rare but potentially fatal clinical emergency, primarily triggered by inhaled volatile anesthetics. It is associated with inherited autosomal-dominant skeletal muscle disorders and typically caused by mutations in ...
Zhixiang Geng +6 more
doaj +2 more sources
Successful management of malignant hyperthermia without dantrolene: A case report [PDF]
Journal of International Medical ResearchMalignant hyperthermia during surgery represents a significant challenge for anesthesiologists due to its high mortality rate and the risk of long-term physiological damage.
Cailing Zhang +3 more
doaj +2 more sources
Caution for psychiatrists: malignant hyperthermia risks with the anesthetic agent succinylcholine (Suxamethonium) during electroconvulsive therapy [PDF]
BMC PsychiatryBackground Malignant hyperthermia is a potentially lethal condition triggered by specific anesthetic drugs, especially a depolarizing muscle relaxant of succinylcholine (Suxamethonium).
Masaki Nakano +8 more
doaj +2 more sources
Acute postoperative sepsis mimicking symptomology suspicious for malignant hyperthermia: case report [PDF]
Revista Brasileira de Anestesiologia, 2020 Background: Sepsis is a life-threatening organ dysfunction with non-specific clinical features that can mimic other clinical conditions with hyper metabolic state such as malignant hyperthermia.
Vendhan Ramanujam +3 more
doaj +3 more sources
Malignant hyperthermia: a case report with a literature review [PDF]
Archives of Aesthetic Plastic Surgery, 2022 Malignant hyperthermia is an extremely rare, potentially lethal disorder that occurs in susceptible patients who are exposed to triggering agents such as volatile anesthetic gases or depolarizing muscle relaxants. The clinical manifestations of malignant
Ji Hoon Kim +4 more
doaj +1 more source
European Journal of Anaesthesiology, 2001 Malignant hyperthermia is an autosomal-dominant inherited disorder of the skeletal muscle cell characterized by a hypermetabolic response to all commonly used inhalational anaesthetics and depolarizing muscle relaxants. The clinical syndrome includes muscle rigidity, hypercapnia, tachycardia and myoglobinuria as result of increased carbon dioxide ...
J K, Kozack, D L, MacIntyre
openaire +5 more sources